Chemistry: analytical and immunological testing – Involving an insoluble carrier for immobilizing immunochemicals – Carrier is inorganic
Reexamination Certificate
2011-08-02
2011-08-02
Cheu, Jacob (Department: 1641)
Chemistry: analytical and immunological testing
Involving an insoluble carrier for immobilizing immunochemicals
Carrier is inorganic
C436S518000
Reexamination Certificate
active
07989221
ABSTRACT:
Assay systems and methods are provided for detecting a target pathogen, such as a microorganism (e.g., bacterium, bacterial toxin) which may be present in a fluid or other location. The method can include linking a magnetic microparticle to a first epitope of the target microorganism in a fluid via a first antibody; utilizing a magnetic field to separate the magnetic microparticle and linked targeted microorganism from at least a portion of other components in the fluid, thereby forming a test sample; linking a glucose molecule to a second epitope of the target microorganism via a second antibody; and detecting the glucose in the test sample to determine the presence or concentration of the target microorganism in the fluid. The glucose detection preferably is one that can be done rapidly, e.g., with a conventional glucometer, and may include measuring the electrical resistance, color, or pH of the test sample.
REFERENCES:
patent: 4289747 (1981-09-01), Chu
patent: 6132607 (2000-10-01), Chen et al.
patent: 2002/0106708 (2002-08-01), Thomas et al.
patent: 2004/0065969 (2004-04-01), Chatterjee et al.
patent: 2004/0146529 (2004-07-01), Selby et al.
Abdel-Hamid, et al., “Flow-through immunofiltration assay system for rapid detection of E. coli O157:H7,” Biosensors & Bioelectronics, 14:309-16 (1999).
Achar, et al., “Diagnosis of acute coronary syndrome,” American Family Physician, 72(1):119-126 (2005).
Adams, et al., “Biochemical markers of myocardial injury is MB creatine kinase the choice for the 1990s?,” Circulation, 88(2):750-763 (1993).
Adams, “Clinical application of markers of cardiac injury: basic concepts and new considerations,” Clinica Chimica Acta, 284(2):127-134 (1999).
Bayliss, “MAFF Research Program FS 12, Detection and Separation of Pathogens and their Toxins,” MAFF UK, Center for Applied Microbiology and Research, Porton Down (1999).
Berroeta, et al., Ann Fr Anesth Reanim, (2005).
Chatterjee, et al., “Size dependent magnetic properties of iron oxide nanoparticles,” Journal of Magnetism and Magnetic Materials, 257:113-118 (2003).
Chen, et al., J. Huazhong Univ Sci Technolog Med Sci 24(5):449-51, 459 (2004).
Cole, et al., “Monoclonal Antibodies and Cancer Therapy,” pp. 77-96 (1985).
Cubrilo-Turek, et al., Acta Med Croatica 58(5):381-8 (2004).
De Winter, et al., “Value of myoglobin, troponin T, and CK-MB mass in ruling out an acute myocardial infarction in the emergency room,” Circulation (http://circ.ahajournals.org/cgi/content/full/92/12/3401), (1995).
Eggers, et al., “Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction,” American Heart Journal, 148 (4):574-581 (2004).
Eggers, et al., Coron Artery Dis 16(5):315-19 (2005).
Eisenman, et al., “Are all troponin assays equivalent in the emergency department,” Singapore Med. J., 46(7):325-327 (2005).
Feldsine, Food Biol. Contam. 80:517-29 (1997).
Galfre, et al.., Nature 266:55052 (1977).
Galvani, et al., “New markers for early diagnosis of acute myocardial infarction,” International Journal of Cardiology, 65 (Suppl.1):S17-S22 (1998).
Gefter, et al., Somatic Cell Genet, 3:231-36 (1977).
Gibler, et al., Ann Emerg Me,. 19:1359-66 (1990).
Haik, et al., “Development of magnetic device for cell separation,” Journal of Magnetism and Magnetic Materials, 194:254-261 (1999).
Héden, et al., “Acute myocardial infarction detected in the 12-lead ECG by artificial neural networks,” Circulation, (http://circ/ahajournals.org/cgi/content/full/96/6/1798), (1997).
Hedges, et al, Ann Emerg Med, 21:1445-50 (1992).
Hudson, et al., “Cardiac markers: point of care testing,” Clinica Chimica Acta, 284(2):223-237 (1999).
Ishii, et al., Clin Chem, (2005).
Johnson, et al., “Comparison of the BAX for screening/e.coli O157:H7 method with conventional methods for detection of extremely low levels of escherichia coli O157:H7 in ground beef,” Applied and Environmental Microbiology, 64(11):4390-4395 (1998).
Kenneth, “Monoclonal antibodies: a new dimension in biological analyses” (1980).
Kim, et al., “Use of chicken egg-yolk antibodies against K88+fimbrial antigen for quantitative analysis of entertoxigenic escherichia coli(ETEC)K88+ by a sandwich ELISA,” J. Sci. Food Agric. 79:1513-1518 (1999).
Kohler, et al., Nature, 256:495-97 (1975).
Kozbor, et al., Immunol Today, 4:72 (1983).
Lerner, Yale J. Biol. Med., 54:387-402 (1981).
Lin, et al., “Rates of positive cardiac troponin 1 and creatine kinase MB mass among patients hospitalized for suspected acute coronary syndromes,” Clinical Chemistry, 50(2):333-338 (2004).
McCarthy, et al., Ann Emerg Med, 22:579-82 (1993).
Ogunjimi, et al., FEMS Immunol. Med. Microbiol, 23:213-20 (1991).
Padhye, et al., “Production and characterization of a monoclonal antibody specific for enterohemorrhagic escherichia coli of serotypes O157:H7 and O26:H11,” Journal of Clinical Microbiology, 29(1):99-103 (1991).
Panteghini, “Diagnostic application of CK-MB mass determination,” Clinica Chimica Acta, 272:23-31 (1998).
Penttila, et al.,Myoglobin, creatine kinase MB isoforms and creatine kinase MB mass in early diagnosis of myocardial infarction in patients with acute chest pain, Clinical Biochemistry, 35(8):647-653 (2002).
Puleo, et al., “Use of a rapid assay of subforms of creatine kinase MB to diagnose or rule out acute myocardial infarction,” New England Journal of Medicine, (file://C:\DOCUME—1\jjdortch\LOCALS˜1\Temp\CYGR8700.htm), (1994).
Roberts, et al., “Earlier diagnosis and treatment of acute myocardial infarction necessitates the need for a ‘new diagnostic mind-set’,” Circulation, 89(2):872-881 (1994).
Sallach, et al., “A change in serum myoglobin to detect acute myocardial infarction in patients with normal troponin 1 levels,” American Journal of Cardiology, 94(7):864-867 (2004).
Shelton, et al., “Evaluation of parameters affecting quantitative detection of Escherichia coli O157 in enriched water samples using immunomagnetic electrochemiluminescence,” Journal of Microbiological Methods, 55:717-725 (2003).
Suter, et al., Molecular Immunology, 26:221-30 (1989).
Van Nieuwenhoven, et al., “Discrimination between myocardial and skeletal muscle injury by assessment of the plasma ratio of myoglobin over fatty acid-binding protein,” Circulation, (http://circ.ahajounrals.org/cgi/content/full/92/10/2848), (1995).
Vote, et al., “Blood glucose meter performance under hyperbaric oxygen conditions,” Clinica Chimica Acta, 305:81-87 (2001).
Wodzig, et al., Eur. J. Clin Chem Clin Biochem, 71:135-40 (1997).
Wright, et al., Epidemiol. Infec., 113:31-39 (1994).
Yu, et al., “Immunomagnetic-electrochemiluminescent detection of escherichia coli O157 and salmonella typhimurium in foods and environmental water samples,” Applied and Environmental Microbiology, 62(2):587-592 (1996).
Yu, et al., “Development of a magnetic microplate chemifluorimmunoassay for rapid detection of bacteria and toxin in blood,” Analytical Biochemistry, 261(1):1-7 (1998).
Cheu Jacob
Do Pensee
Florida State University Research Foundation
Sutherland & Asbill & Brennan LLP
LandOfFree
Assays and systems for rapid detection of pathogens does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Assays and systems for rapid detection of pathogens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assays and systems for rapid detection of pathogens will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2734798